Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Change in Accured Expenses (2020 - 2025)

BioAtla's Change in Accured Expenses history spans 6 years, with the latest figure at -$747000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 76.49% year-over-year to -$747000.0; the TTM value through Dec 2025 reached $2.8 million, up 120.83%, while the annual FY2025 figure was $2.8 million, 120.83% up from the prior year.
  • Change in Accured Expenses reached -$747000.0 in Q4 2025 per BCAB's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.3 million in Q2 2022 to a low of -$9.0 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $301500.0, with a median of $269000.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: crashed 2179.49% in 2022, then surged 229.51% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$2.9 million in 2021, then soared by 74.23% to -$735000.0 in 2022, then plummeted by 886.26% to -$7.2 million in 2023, then surged by 56.17% to -$3.2 million in 2024, then skyrocketed by 76.49% to -$747000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Change in Accured Expenses are -$747000.0 (Q4 2025), $1.0 million (Q3 2025), and $421000.0 (Q2 2025).